Effect of blood-brain barrier disruption on intact and fragmented monoclonal antibody localization in intracerebral lung carcinoma xenografts

Edward Neuwelt, P. A. Barnett, K. E. Hellstrom, I. Hellstrom, C. I. McCormick, F. L. Ramsey

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

These studies highlight several factors that affect monoclonal antibody (Mab) localization to a tumor in the brain, including tumor permeability, nonspecific and specific binding, plasma half-life, radiolabeled antibody stability and the blood-brain barrier. Methods: A pancarcinoma Mab [L6 IgG, F(ab')2 and Fab] and an irrelevant isotype-matched antibody [P1.17 IgG and F(ab')2] were given with and without osmotic blood-brain barrier disruption in a LX-1 human small-cell lung carcinoma intracerebral xenograft model. Results: Intracerebral tumor size and permeability to antibody increased with the selection of 10, 14 or 17 days postinoculation when antibody was administered. Barrier disruption increased the delivery, particularly at earlier time points, which was dependent on antibody-specific and nonspecific binding and tumor permeability. Dehalogenation and/or antibody binding stability also appeared to affect the percent delivery. Conclusion: These studies demonstrate important variables that should be considered when clinical trials are designed or Mab delivery and localization in intracerebral tumor models are evaluated.

Original languageEnglish (US)
Pages (from-to)1831-1841
Number of pages11
JournalJournal of Nuclear Medicine
Volume35
Issue number11
StatePublished - 1994

Fingerprint

Blood-Brain Barrier
Heterografts
Monoclonal Antibodies
Carcinoma
Lung
Antibodies
Permeability
Neoplasms
Immunoglobulin G
Small Cell Lung Carcinoma
Brain Neoplasms
Half-Life
Clinical Trials

Keywords

  • blood-brain barrier
  • monoclonal antibody
  • xenografts

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Effect of blood-brain barrier disruption on intact and fragmented monoclonal antibody localization in intracerebral lung carcinoma xenografts. / Neuwelt, Edward; Barnett, P. A.; Hellstrom, K. E.; Hellstrom, I.; McCormick, C. I.; Ramsey, F. L.

In: Journal of Nuclear Medicine, Vol. 35, No. 11, 1994, p. 1831-1841.

Research output: Contribution to journalArticle

Neuwelt, Edward ; Barnett, P. A. ; Hellstrom, K. E. ; Hellstrom, I. ; McCormick, C. I. ; Ramsey, F. L. / Effect of blood-brain barrier disruption on intact and fragmented monoclonal antibody localization in intracerebral lung carcinoma xenografts. In: Journal of Nuclear Medicine. 1994 ; Vol. 35, No. 11. pp. 1831-1841.
@article{9146f2e6a7334802858e7dc113522aeb,
title = "Effect of blood-brain barrier disruption on intact and fragmented monoclonal antibody localization in intracerebral lung carcinoma xenografts",
abstract = "These studies highlight several factors that affect monoclonal antibody (Mab) localization to a tumor in the brain, including tumor permeability, nonspecific and specific binding, plasma half-life, radiolabeled antibody stability and the blood-brain barrier. Methods: A pancarcinoma Mab [L6 IgG, F(ab')2 and Fab] and an irrelevant isotype-matched antibody [P1.17 IgG and F(ab')2] were given with and without osmotic blood-brain barrier disruption in a LX-1 human small-cell lung carcinoma intracerebral xenograft model. Results: Intracerebral tumor size and permeability to antibody increased with the selection of 10, 14 or 17 days postinoculation when antibody was administered. Barrier disruption increased the delivery, particularly at earlier time points, which was dependent on antibody-specific and nonspecific binding and tumor permeability. Dehalogenation and/or antibody binding stability also appeared to affect the percent delivery. Conclusion: These studies demonstrate important variables that should be considered when clinical trials are designed or Mab delivery and localization in intracerebral tumor models are evaluated.",
keywords = "blood-brain barrier, monoclonal antibody, xenografts",
author = "Edward Neuwelt and Barnett, {P. A.} and Hellstrom, {K. E.} and I. Hellstrom and McCormick, {C. I.} and Ramsey, {F. L.}",
year = "1994",
language = "English (US)",
volume = "35",
pages = "1831--1841",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "11",

}

TY - JOUR

T1 - Effect of blood-brain barrier disruption on intact and fragmented monoclonal antibody localization in intracerebral lung carcinoma xenografts

AU - Neuwelt, Edward

AU - Barnett, P. A.

AU - Hellstrom, K. E.

AU - Hellstrom, I.

AU - McCormick, C. I.

AU - Ramsey, F. L.

PY - 1994

Y1 - 1994

N2 - These studies highlight several factors that affect monoclonal antibody (Mab) localization to a tumor in the brain, including tumor permeability, nonspecific and specific binding, plasma half-life, radiolabeled antibody stability and the blood-brain barrier. Methods: A pancarcinoma Mab [L6 IgG, F(ab')2 and Fab] and an irrelevant isotype-matched antibody [P1.17 IgG and F(ab')2] were given with and without osmotic blood-brain barrier disruption in a LX-1 human small-cell lung carcinoma intracerebral xenograft model. Results: Intracerebral tumor size and permeability to antibody increased with the selection of 10, 14 or 17 days postinoculation when antibody was administered. Barrier disruption increased the delivery, particularly at earlier time points, which was dependent on antibody-specific and nonspecific binding and tumor permeability. Dehalogenation and/or antibody binding stability also appeared to affect the percent delivery. Conclusion: These studies demonstrate important variables that should be considered when clinical trials are designed or Mab delivery and localization in intracerebral tumor models are evaluated.

AB - These studies highlight several factors that affect monoclonal antibody (Mab) localization to a tumor in the brain, including tumor permeability, nonspecific and specific binding, plasma half-life, radiolabeled antibody stability and the blood-brain barrier. Methods: A pancarcinoma Mab [L6 IgG, F(ab')2 and Fab] and an irrelevant isotype-matched antibody [P1.17 IgG and F(ab')2] were given with and without osmotic blood-brain barrier disruption in a LX-1 human small-cell lung carcinoma intracerebral xenograft model. Results: Intracerebral tumor size and permeability to antibody increased with the selection of 10, 14 or 17 days postinoculation when antibody was administered. Barrier disruption increased the delivery, particularly at earlier time points, which was dependent on antibody-specific and nonspecific binding and tumor permeability. Dehalogenation and/or antibody binding stability also appeared to affect the percent delivery. Conclusion: These studies demonstrate important variables that should be considered when clinical trials are designed or Mab delivery and localization in intracerebral tumor models are evaluated.

KW - blood-brain barrier

KW - monoclonal antibody

KW - xenografts

UR - http://www.scopus.com/inward/record.url?scp=0027986952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027986952&partnerID=8YFLogxK

M3 - Article

VL - 35

SP - 1831

EP - 1841

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 11

ER -